

## Situational Analysis of Leishmaniasis Research in Kenya

Willy Kiprotich Tonui

*Kenya Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya*

### SUMMARY

*Leishmania spp* are protozoan parasites of the Trypanosomatidae family that cause disease in humans and animals. In general, infections with these parasites can be divided into three main forms namely, cutaneous, mucocutaneous, and visceral leishmaniasis. The disease is prevalent in many tropical and subtropical regions of the world, where it is transmitted via the bite of an infected sand fly. Leishmaniasis has been known to be endemic in parts of Kenya from as far back as early in the 20<sup>th</sup> century. These endemic areas include Turkana, Baringo, Kitui, Machakos, Meru, West Pokot and Elgeyo Marakwet districts which have been reported to be endemic for kala-azar. Recent outbreaks of VL have been reported in the previously non-endemic districts of Wajir and Mandera in North Eastern Kenya between May 2000 and August 2001. The vector for VL in Kenya is *Phlebotomus martini* though other vectors including *P. orientalis* have been reported. Baringo district is the only foci reported where both VL and CL are known to occur in Kenya. The aetiological agents for CL which include *L. major* which has been reported in Baringo; *L. tropica* in Laikipia, Samburu, Isiolo, Nakuru and Nyandarua districts while *L. aethiopica* has been reported in the Mt Elgon area. In Kenya, *P. duboscqi*, *P. guggisbergi* have been shown to be the vectors of *L. major* and *L. tropica*, respectively, while *P. pediffer*, *P. longipes* and *P. elgonensis* have been implicated as vectors of *L. aethiopica*. Since 1980, the Kenya Medical Research Institute (KEMRI) has spearheaded research on leishmaniasis research in Kenya focusing on various aspects including characterization of *Leishmania* species, biology, and ecology of sand fly vectors, development of biological strategies for sand fly control, identification of animal reservoirs, diagnosis, new treatment strategies, new chemotherapeutic agents, and vaccine-related studies. KEMRI, a founding partner of the Drugs for Neglected Disease Initiative (DNDi), whose overall aim is to address lack of new or improved drugs for neglected diseases (which include leishmaniasis, malaria, trypanosomiasis and chagas disease) has made major contributions in leishmaniasis research and control in Kenya and the eastern Africa region.

*[Afr J Health Sci. 2006; 13: 7-21]*

### Introduction

*Leishmania spp* are protozoan parasites of the Trypanosomatidae family that cause disease in humans and animals. In general, infections with these parasites can be divided into three main forms namely, cutaneous (CL), mucocutaneous (MCL) and visceral (VL) (or kala azar) leishmaniasis [1]. The disease is prevalent in many tropical and subtropical regions of the world, where it is transmitted via the bite of an infected sand fly. Although leishmaniasis is endemic in 88 countries, 90% of CL cases have been reported in Afghanistan

Syria, Saudi Arabia, Brazil, and Peru. VL, also known as kala azar, is the most dangerous form of the disease and occurs in Bangladesh, Brazil, India, and Sudan. A new syndrome in which *Leishmania* co-infects patients with AIDS is particularly deadly and has been reported in 33 countries including Kenya [1, 2]. The impact of leishmaniasis on humans is enormous. One tenth of the world's population is at risk and 2 million new cases are reported each year [1]. There are 22 species that cause disease in humans or animals [3] and specific

## PERSPECTIVE

parasite species are associated with specific types of syndrome (see Table 1). For example, VL is caused by *L. donovani* and *L. chagasi* [4] whereas CL is caused by different species in different areas of the world. For example, *L. major* causes CL in the Middle East and *L.*

*mexicana* causes CL in Central America. In addition, lesions caused by *L. braziliensis* complex in the skin can spread to the mucous membranes resulting in a late complication known as MCL, or espundia [5].

**Table 1: Spectrum of leishmaniases, aetiological agents and worldwide distribution**

Type of leishmaniasis	Causative organism	Worldwide distribution
Visceral	<i>L. donovani</i> <i>L. infantum</i> <i>L. chagasi</i>	China, India, Iran, Sudan, Kenya, Ethiopia, Mediterranean basin, Brazil, Colombia, Venezuela, Argentina
Cutaneous	<i>L. tropica</i> <i>L. major</i> <i>L. aethiopica</i> <i>L. mexicana</i>	Mediterranean basin, Afghanistan, Middle East, W. and N. Africa, Kenya, Ethiopia, Central America and Amazon basin
Mucocutaneous	<i>L. braziliensis</i> <i>complex</i>	Brazil, Peru, Ecuador, Columbia, Venezuela

### ***Epidemiology of leishmaniases in Kenya***

Leishmaniasis has been known to be endemic in parts of Kenya from as far back as early in the 20<sup>th</sup> century [6]. An outbreak of VL in the King's African Rifles troops encamped north of Lake Turkana in southwest Ethiopia was reported in the 1940s [7]. Since then Turkana, Baringo, Kitui, Machakos, Meru, West Pokot and Elgeyo Marakwet districts have been considered to be endemic for kala-azar. Between 1950 and 1960 more than 1,052 cases of VL were reported from these districts alone [6].

A serious outbreak of VL was reported in Kitui district that began in 1952 with 303 cases being reported and peaked in 1953 with 2,142 cases. In the same year 157 cases were reported in the neighbouring Meru district [6]. Another outbreak of VL in Meru district was reported in 1966 with 1,500 cases [8]. *Phlebotomus martini* Parrot, 1936 was shown to be the vector of kala-azar during that epidemic [9, 10]. Further outbreaks of VL were reported in Machakos district in the 1970s, and again in Kitui district in the 1980s [11-13]. Baringo and the neighbouring districts such as West Pokot were first identified as leishmaniases foci in 1955 [14]. Since then, *L. donovani* transmitted by *P. martini* and *L. major* transmitted by *P.*

*duboscqi* Neveu Lemaire, 1906 have been shown to exist in the region allopatrically, with rodents being the reservoir of CL (15-21). Other possible vectors that have been reported include *P. celiae* Minter, 1962, *P. vansomeranae* Heich, Guggisberg *et* Teesdale, 1956 and *Sergentomyia garnhami* [22] for VL [23, 24]. VL caused by *L. donovani*, is endemic in Baringo District, Kenya. The disease occurring in Baringo has a focal distribution in the dry, hot areas below 1500 metres and the infections may be characterized as follows: 1) asymptomatic 2) subclinical and self-limiting (not medically identifiable), and 3) clinically manifest disease (that is medically identifiable). Half of the reported VL patients are between 5 and 14 years of age and 66% of them are males. A human case of a mixed *L. donovani* and *L. major* infection has been reported in this dual focus of VL and CL [25]. Often associated with sporadic incidents of the disease rather than epidemics, as many as 305 cases of VL were reported in Baringo district alone in 1999 [26-29]. In the early 1990s, 3 Maasai children were diagnosed with VL acquired locally in Kajiado district in the Rift Valley of Kenya. *L. donovani s.l.* was isolated but a survey of other school children in the district did not reveal any more cases. *P. martini* was found to be common in the area

## PERSPECTIVE

---

while *P. orientalis* Parrot, 1936 another vector for VL though present was rare and therefore transmission was attributed to *P. martini* [30]. More recently, an outbreak of VL was reported in the previously non-endemic Wajir and Mandera districts of North Eastern Kenya where during a period from May 2000 to August 2001, 904 patients were diagnosed with VL, with the patients coming from an area that spanned Wajir and Mandera districts, southern Somalia and southeast Ethiopia. Unusual rainfall patterns, malnutrition and migration of a *Leishmania*-infected population seeking food and security are thought to have contributed to this outbreak [31].

Diffuse cutaneous leishmaniasis (DCL) was first described in Kenya in 1969 with 3 patients from the indigenous communities in Bungoma district, around the Mt. Elgon area diagnosed [32]. *L. aethiopica* has since been identified as the aetiological agent, rodents as the animal reservoirs and *P. pedifer* Lewis, Mutinga *et* Ashford, 1972 to be the vector of DCL in the Mt. Elgon region [14, 33, 34].

Cutaneous leishmaniasis caused by *L. major*, and transmitted by *P. duboscqi* was first reported in Kitui district in the 1990s [35]. *L. major* has also been isolated from an infected monkey (*Cercopithecus aethiops*) from Kiambu District, central Kenya [36]. However, no human cases have been reported from the district so far.

Meanwhile, active case detection and investigations of sand fly resting places conducted in the early 1990s, led to the identification of *L. tropica* CL in Central and Rift Valley provinces, mainly Laikipia, Samburu, Isiolo, Nakuru and Nyandarua districts [34]. Three sand fly species belonging to the subgenus *Larrousius* namely, *P. pedifer*, *P. aculeatus* Lewis, Minter *et* Ashford, 1974, *P. guggisbergi* Kirk *et* Lewis, 1952 and one *Paraphlebotomus* species (*P. saevus* Parrot *et* Martin, 1932) were found to be common in these areas [34,37-39]. *P. guggisbergi* has since been shown to be the vector for *L. tropica* in Kenya [40].

### **Contributions of the Kenya Medical Research Institute (KEMRI) to leishmaniasis research and control in Kenya**

Currently, disease control strategies rely on chemotherapy to alleviate the disease, on vector suppression, and personal protection to reduce transmission [1]. To date, there are no proven vaccines against any form of leishmaniasis [41]. Since 1980, the Kenya Medical Research Institute (KEMRI) has made major contributions to leishmaniasis research and control focusing on various aspects including characterization of *Leishmania* species, biology, and ecology of sand fly vectors, development of biological strategies for sand fly control, identification of animal reservoirs, diagnosis, new treatment strategies, new chemotherapeutic agents, and vaccine-related studies.

This has been achieved through collaborations with several agencies including the UN Development Program/World Bank/World Health Organization Special Program for Research and Training in Tropical Diseases (TDR), US Army Medical Research Unit-Kenya (USAMRU-K), the Ministry of Health's Division of Vector Borne Diseases (DVBD), International Centre for Insect Physiology and Ecology (ICIPE), the Institute for Primate Research (IPR), Médecins Sans Frontières (MSF), local and international universities and colleges. As a result of this KEMRI scientists regularly participate in the Ministry of Health's Disease Outbreak Management Unit, (DOMU), WHO and MSF to assist in the control of Kala azar outbreaks in Kenya and in the eastern African region. The Centre for Biotechnology Research and Development (CBRD) and the Centre for Clinical Research (CCR) of KEMRI have spearheaded leishmaniasis research. The Institute is a leader in sand fly biology research and it maintains the only sand fly colony in sub-Saharan Africa. The Centre for Clinical Research (CCR), designated a Good Clinical Practice (GCP) compliant facility, has also been involved in testing new anti-leishmanial drugs. KEMRI has an animal care facility that supports laboratory research in leishmaniasis.

The following sections summarize research activities on leishmaniasis in Kenya in which KEMRI has been a major contributor.

### ***Characterization of Leishmania species in Kenya***

It is essential to know the identity of the parasite(s) in each focus, since this knowledge has implications for control and treatment of leishmaniasis [42]. Therefore, isolates originating either from research, entomological and zoological activities should be identified and compared with international references stains. Cryobanks are also required for storage and for future availability. To address this need, a laboratory at CBRD of KEMRI was designated a regional reference centre for leishmaniasis taxonomy in Kenya. This facility maintains a cryobank of *Leishmania* isolates and is internationally referred to as Nairobi Leishmania Bank (NLB). At least 1800 *Leishmania* and other *Leishmania*-like isolates obtained from humans, other vertebrates, sand fly vectors and other arthropods from Kenya and other parts of Africa have been cryopreserved in this bank.

Through this bank it has been possible to compare the biological characteristics of the *Leishmania* parasites in Kenya and the neighbouring countries [43]. Zymodeme analysis of the Kenyan VL and CL isolates resulted in the identification of 11 subpopulations of the *L. donovani* species complex and six subpopulations of the *L. tropica* species complex endemic to different geographic areas of Kenya [37, 39]. A *Leishmania*-like isolate from the reptiles has since been identified as *Sauroleishmania* (RGER/KE/89/NLB-1236) and has been shown experimentally to cause *L. major*-like cutaneous lesions and visceral leishmaniasis in BALB/c mice [44].

### ***Research on sand fly biology and control in Kenya***

Control of phlebotomine sand flies remains a difficult problem throughout the world because of the insects' very highly specialized breeding sites. Use of insecticides remains the most effective method of sand fly control. However, resistance to insecticides has proved to be a major challenge. Use of bed nets or permethrin impregnated wall cloth, repellents and other personal protective measures have proved to be unreliable in Kenya [45]. With

these shortcomings, there is need to identify new insecticides.

In general, control of leishmaniasis is hampered by the diversity of vectors, parasites, and reservoir hosts and the interventions must take into account these differences. It is therefore crucial to understand the biology of the leishmaniasis as well as that of the sand fly. The exploration of host-parasite interactions between species of *Leishmania* and respective vectors represents a wide and important field for basic and applied research as well. To address these needs, laboratory reared sand fly colonies have been established at KEMRI. These include *P. martini* and *P. duboscqi* Neveu-Lemaire (Diptera: Psychodidae) [17]. It is through studies done using *P. duboscqi* that *L. major* development within the sand fly was unravelled [46]. These studies have shown that it takes a period of 4-25 days, for the parasite to develop inside the sand fly and during the next blood meal the infective metacyclic stage enters the body of host through a sand fly bite [46, 47]. At least five developmental forms have also been recognized during development in the subgenus *Leishmania*, namely, procyclic promastigotes, nectomonad promastigotes, haptomonad promastigotes, paramastigotes, and metacyclic promastigotes [46].

Understanding of sand fly biology is also important in designing new control programmes in leishmaniasis. It has also been shown that *P. perniciosus* can acquire and allow the development of *L. infantum* by feeding on *L. infantum*/HIV coinfecting patients. Since this sand fly is an important vector of VL in southern Europe, a new natural anthroponotic cycle could be considered in the epidemiology of *L. infantum*/HIV coinfection [48]. This phenomenon is known as xenodiagnosis and this technique has been shown to be able to detect the presence of *Leishmania* parasites in a patient that other conventional diagnostic techniques failed (48). Therefore, the design of leishmaniasis control programs and the management of coinfecting individuals should take these findings into account in southern Europe [48].

Investigations on vectors of leishmaniasis in Kenya started only in the early 1950's when the VL assumed importance as a result of a

## PERSPECTIVE

---

major disease epidemic outbreak [49]. Since then these investigations on vectors have resulted in identification of the main vectors for both VL and CL. *P. martini* Parrot has been confirmed as the vector for *L. donovani* the aetiological agent of VL in Kenya, southern Sudan, and Ethiopia [15, 21,50]. This sand fly species rests and breeds in termite hills, animal burrows, tree holes, and house walls [51, 52]. It feeds mainly on goats, rabbits, and humans, and to a lesser extent on dogs, cattle, and other hosts [52]. Another vector for *L. donovani* in Kenya is *P. orientalis* which occurs in Kajiado district of Kenya [30].

Among the cutaneous forms of leishmaniasis *P. duboscqi* Neveu-Lemaire (Diptera: Psychodidae) has been confirmed as the main vector of *L. major* in West Africa and the Rift Valley of Kenya [53, 54]. *P. pediffer*, *P. longipes* and *P. elgonensis* have been implicated as vectors of *L. aethiopica* occurring in the vicinity of Mount Elgon, Kenya [32, 34, 55, 56]. *P. guggisbergi* has been incriminated as a vector of *L. tropica* endemic in Samburu, Laikipia, Narok, Nakuru and Nyandarua districts of Kenya [37, 40].

### **Research on animal reservoirs of *Leishmania* in Kenya**

Extensive research has been carried out in eastern Africa for animal reservoirs of both VL and CL. The domestic dog [54] has been the only domestic animal so far implicated as a possible reservoir for visceral leishmaniasis [58]. For cutaneous leishmaniasis caused by *L. aethiopica*, the rock (*Denobryax arboveus*) and tree (*Procapra johnstoni*) hyraxes and the giant rat (*Cricetomys sp*) are the proven reservoirs of the disease [33], while several species of rodents have been demonstrated to harbor *L. major* which include *Tatera robusta*, *Arvicanthis niloticus* and *Aethomys kaiseri* [15, 18, 19]. The domestic sheep [58] and goats [59] which were initially suspected to be animal reservoirs for VL have since been proven experimentally to be non susceptible to *L. donovani* infection and therefore unlikely to be a synanthropic reservoir of this parasite [60, 61]

In Kenya, anthroponotic VL in Baringo District has shown that *Leishmania*

deoxyribonucleic acid (DNA) is detectable in patients 10.5 months before diagnosis, up to 3 years after diagnosis and apparently successful treatment. Sub clinical cases have also been reported to have detectable circulating parasite DNA in their blood. These findings may indicate that sub clinical cases can be a reservoir and formerly treated VL patients can remain a reservoir for a long time. Xenodiagnosis may be important in such areas to determine whether sub clinical cases and former VL patients do have role in transmission of VL in Kenya [62].

### **Research on new diagnostic tests for leishmaniasis**

Sensitive, specific, reproducible, feasible and cheap diagnostic tests are needed if one wants to build an effective and efficient test-treatment strategy [63]. Since Leishman identified the parasite in 1901, the definitive diagnosis of VL has relied on demonstrating the organism by microscopy in smear or culture of aspirates or tissue [64,65]. However, a splenic-aspiration technique [66] which is used to acquire these tissues can hardly be recommended for rural district hospitals because of the risk of fatal haemorrhage, which subsists even with the recently introduced safer procedures [67]. Therefore, the search for a suitable alternative for splenic aspirates is thus still going on.

Over the past 20 years, several serological tests have been developed showing high sensitivity for visceral disease [68]. Enzyme linked immunosorbent assays (ELISA) for detecting leishmanial antibodies has also been established and successfully applied in clinical routine and sero-epidemiological surveys in Kenya [26, 27, 69]. Of all the available serological tests, the direct agglutination test (DAT) has proved to be the most appropriate one for field use in Kenya [29, 63, 70, 71].

Other methods that have been tested include isoenzyme analysis [72, 73]; kDNA based techniques [74, 75]. In recent years polymerase chain reaction (PCR) techniques for leishmaniasis have been developed and applied to visceral disease with contradictory results [76, 77]. Apart from the fact that PCR does not eliminate the need for tissue

sampling, it is not exactly the type of appropriate technology needed in endemic areas.

### ***Research on new treatment strategies and chemotherapeutic agents for leishmaniasis***

Neglected diseases such as leishmaniasis, trypanosomiasis, Chagas disease, and malaria have had a devastating impact on the world's poor. These treatable, infectious tropical diseases have been progressively marginalized by those in charge of making research programme decisions, both in the public and private sectors. Unfortunately, people suffering from these diseases do not constitute a market lucrative enough to attract investment in research and development for new drugs. KEMRI is a founding partner of an international effort, Drugs for Neglected Disease Initiative (DNDi), whose aim is to address lack of new or improved drugs for neglected diseases such as leishmaniasis. KEMRI's Centre for Clinical Research (CCR) brings to DNDi a rich history of involvement in tropical diseases and expertise in clinical research for neglected diseases.

Over the last 25 years, scientists at CCR have been addressing the issue of treatment options for Kala-azar. The treatment of leishmaniasis, as currently conducted in Kenya with sodium stibogluconate, is unsatisfactory as it is expensive, resistance and relapses may occur [78]. However, it is through collaborative efforts of CCR scientists several new drugs or including AmBisome® a safer and more effective lipid formulation of Amphotericin B (second line VL treatment); sitamaquine and aminosidine, alone or combined with sodium stibogluconate, in visceral leishmaniasis, compared to treatment by stibogluconate alone have been tested [79].

Worldwide, *Leishmania* parasites are increasingly becoming more and more resistant to antileishmanial drugs. The increment of *in vitro* antimony resistance due to intermittent drug exposure [80-83], the isolation of antimony-resistant *Leishmania* strains from patients with unresponsive CL [84,85], and recent reports, of numerous cases of VL among patients with the human immunodeficiency virus [86-89] indicate the need for new therapeutic agents for control

and management of leishmaniasis. Extensive studies of new drugs with antileishmanial activities, including natural products and synthetic compounds, have been undertaken worldwide [90], but problems associated with the currently available drugs remain unresolved. In recent years, there has been growing interest in alternative therapies and use of natural products, especially those derived from plants [91]. The use of plant-based medicine for healing and prophylaxis is as ancient and universal as medicine itself. Recent research undertaken in KEMRI has led to discovery of plant-based products with antileishmanial activities. For instance, studies have shown that leaf, root and stem extracts from *Ajuga remota* and *Trichilla emetica* have antileishmanial activity when tested against *L. donovani* *in vitro* and *in vivo* [92]. Some of the active compounds isolated from plants include iridoid glucosides, limonoids and terpenoids [92]. KEMRI has also initiated studies aimed at testing extracts/compounds from medicinal plants used widely by the local people for treating splenomegaly related ailments in leishmaniasis endemic areas of Kenya [92]. A long term goal of this research is to develop oral drugs for leishmaniasis. These drugs have an advantage of reducing treatment-related socioeconomic difficulties (inadequate health care infrastructure and the long period of patient hospitalization) prevalent in the endemic areas.

Among the products tested for antileishmanial activity in the rodent models (BALB/c mice and Syrian hamsters) at KEMRI includes metal ion chelators namely (Pristane, EGTA, and HEEDTA). Results of these studies suggests that metal ions chelators have antileishmanial potential *in vivo* against *L. donovani* but their activity was low compared to that of Pentostam [93, 94].

### ***Vaccine related research for leishmaniasis in Kenya***

Currently there is no vaccine available for use against any form of leishmaniasis worldwide [41]. In brief, vaccines based on killed promastigotes with or without *Mycobacterium bovis* BCG have shown significant protection against *L. braziliensis* [95], *L. mexicana* or *braziliensis*, *L. major* [96] and *L. donovani* [97] in humans. In experimental animal

## PERSPECTIVE

---

models, several other vaccine preparations are being tested. Examples include: attenuated live parasites [98]; subunit vaccines delivered by live carriers such as BCG expressing the surface protease gp63 of *L. major* [99]; vaccinia virus expressing the glycoprotein gp46/M2/PSA-2 [100]; gp63 expressed in attenuated *Salmonella typhimurium* [101]; purified recombinant or native proteins formulated with an adjuvant such as the *Leishmania*-homologue of receptors for activated C kinase (LACK) plus IL-12 [103, 102], gp46/M2/PSA-2 or protein dp 72 plus *Corynebacterium parvum* [104], T cell epitopes plus Poloxamer 407 [104]; and vaccination with DNA encoding gp63 [105], LACK [106], or gp46/M2/PSA-2 [107]. In general, these vaccination protocols elicited partial protection against *L. major*.

Vaccine research at KEMRI is still at the rodent model stage of development in leishmaniasis. So far live-attenuated *L. major* parasites [108], *L. major* culture-derived soluble exogenous antigens (SEAgS) [109], lipophosphoglycan (LPG) alone or LPG plus *Mycobacterium bovis* Bacille Calmette-Guerin (BCG) [110], and LPG plus salivary gland lysates [111] have been tested.

Transmission blocking vaccine studies in leishmaniasis have also been undertaken at KEMRI. These studies have shown that LPG is an excellent candidate as a transmission blocking vaccine against *L. major* infections [112,113]. In these studies, sand flies, which fed on BALB/c mice, immunized with *L. major*-derived LPG [114] or monoclonal antibodies raised against LPG [115] showed that parasite development was inhibited at the log phase (procyclic) of the parasite. There was also a marked reduction in the numbers of metacyclic promastigotes developing, leading to reduced transmission of *L. major* to naive BALB/c mice [113]. It has also been shown that *P. dubosqi* gut lysates and proteins present in *L. major*-derived LPG share two common proteins of molecular weights 105 kDa and 106 kDa [115]. The goal of these studies has been to develop a vaccine that can be utilized both to reduce transmissible infections within the sand fly and disease severity within the host. Some of the important findings relevant to vaccine research also

include the determination of an inoculum dose required for effecting a visceral infection in rodents [116].

At the Institute for Primate Research (IPR) in Karen, Nairobi it has been shown that the vervet monkey (African Green monkey) is a good model for human cutaneous or visceral leishmaniasis [117, 118]. Availability of a non-human primate model of leishmaniasis facilitates the study of different aspects of this disease and will accelerate the development of vaccines and new drugs for leishmaniasis. Using this model the safety and immunopotency of the recombinant gp63 mixed with Bacille Calmette Guerin (BCG) vaccines [119], and also the adjuvant potential of two doses of IL-12 when used with a killed *L. major* vaccine [120] have been evaluated. It has also been demonstrated that high cross-reactivity between *L. donovani* and *L. major*, and that *L. donovani* protects against *L. major* infections [121]. These findings have relevance for vaccine development in leishmaniasis.

## Conclusion

Although various aspects of the transmission and control of leishmaniasis have been studied in Kenya, the impact of visceral leishmaniasis or kala azar is still enormous in Kenya. Control measures against sand flies and reservoir hosts need to be further evaluated in terms of their effect on disease incidence. Very few attempts have also been made to quantify local factors or to identify the causative mechanisms of epidemics in previously nonendemic or low endemic areas. Research to develop more effective drugs that meet the current standards of safety also remains a high priority. It is hoped that the entry of Drugs for Neglected Disease Initiative (DNDi), whose aim is to address lack of new or improved drugs for neglected diseases including leishmaniasis will mobilize inter-country, international support and collaboration in terms of both finance and technical expertise towards achieving this goal. Diagnostic and vaccine-related studies are also still required to be pursued vigorously.

Many cases of leishmaniasis still go unreported or undiagnosed hence the official statistics are currently not available for

## PERSPECTIVE

---

determining the actual number of cases in Kenya. Health education activities are still required to sensitize people living in endemic areas, medical and public health managers, and individuals at risk on leishmaniasis. Decision makers should be sensitized on the importance of the leishmaniasis as a public health problem so that they will support and defend control programmes. Notwithstanding these challenges, contributions from KEMRI and its partners towards leishmaniasis control in Kenya and the eastern Africa region is commendable.

### References

1. World Health Organization leishmaniasis control homepage: <http://www.who.int/emc/diseases/leish/index.html>.
2. Desjeux P. *Leishmania* / HIV co-infections. *African Health* 1995; **18**(1):20-2.
3. Marsella R; and Ruiz de Gopegui R. Leishmaniasis: a re-emerging zoonosis. *International Journal of Dermatology* 1998; **37**: 801-814.
4. Hide G; and Tait A. The molecular epidemiology of parasites. *Experientia* 1991; **47**:128-142.
5. Pirmez C. Immunopathology of American cutaneous leishmaniasis. *Memorias do Instituto Oswaldo Cruz* 1992; **5**:105-109.
6. Fendall NR. The spread of kala-azar in Kenya. *East African Medical Journal* 1961; **38**: 417-419.
7. Cole ACE; Cosgrove PC. and Robinson G. A preliminary report of an outbreak of kala-azar in a battalion of King's African Rifles. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1942; **36**: 25-34.
8. Wijers DJ. and Minter DM. Studies on the vector of kala-azar in Kenya. V. The outbreak in Meru district. *Annals of Tropical Medicine and Parasitology* 1966; **60**(1): 11-21.
9. Heisch RB; Wijers DJ. and Minter DM. In pursuit of the vector of kala-azar in Kenya. *BMJ*, 1962; **5298**: 1456-1458.
10. Wijers DJB. and Mwangi S. Studies on the vector of kala-azar in Kenya. VI. Environmental epidemiology in Meru district. *Annals of Tropical Medicine and Parasitology* 1966; **60**(3): 373-391.
11. Ngoka JM. and Mutinga MJ. Visceral leishmaniasis in Kenya: The onset of an epidemic outbreak in the Machakos district of Kenya. *East African Medical Journal* 1978; **55**(7): 328-331.
12. Ho M; Siongok TK; Lyerly WH. and Smith DH. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1982; **76**(6): 741-746.
13. Wijers DJ. and Kiilu G. Studies on the vector of kala-azar in Kenya, VIII. The outbreak in Machakos District: epidemiological features and a possible way of control. *Annals of Tropical Medicine and Parasitology* 1984; **78**(6): 597-604.
14. Mutinga MJ. *Phlebotomus* fauna in the cutaneous leishmaniasis focus of Mt. Elgon, Kenya. *East African Medical Journal* 1975; **52**:307-7.
15. Heisch RB. The isolation of *Leishmania* from a ground squirrel in Kenya. *East African Medical Journal* 1957; **34**:183.
16. Heisch RB; Grainger WE. and Harvey AE. The isolation of a *Leishmania* from gerbils in Kenya. *Journal of Tropical Medicine and Hygiene* 1959; **62**(7): 158-159.
17. Beach R; Young DG. and Mutinga MJ. *Phlebotomus (Phlebotomus) duboscqi* from Kenya: a new record. *Transactions of the Royal Society and Tropical Medicine and Hygiene* 1982; **76**: 707-708.
18. Githure JI; Beach RF. and Lightner LK. The isolation of *Leishmania major* from rodents in Baringo District, Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1984; **78**: 283.
19. Githure JI; Schnur LF; Blancq SM. and Hendricks LD. Characterizations of Kenyan *Leishmania* spp. and identification of *Mastomys natalensis*, *Tartermys emini* and *Aethomys kaiseri* as new hosts of *L. major*. *Annals of Tropical Medicine and Parasitology* 1986; **80**: 501-507.
20. Muigai R; Githure JI; Gachihi GS; Were JB; Leuweenburg J. and Perkins PV. Cutaneous leishmaniasis caused by *Leishmania major* in Baringo District, Kenya. *Transactions of the Royal Society*



## PERSPECTIVE

---

- for *Tropical Medicine and Hygiene* 1987; **81**: 600-602.
21. Perkins PV; Githure JI; Mebrahtu Y; Kiilu G; Anjili C; Ngumbi PS; Nzovu J; Oster CN; Whitmire RE; Leeuwenburg J; Hendricks LD. and Koech DK. The isolation of *Leishmania donovani* from *Phlebotomus martini* collected in Baringo District, Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1988; **82**: 695-700.
  22. Heisch RB. Zoonoses as a study in ecology; with special reference to plague, relapsing fever, and leishmaniasis. *British Medical Journal* 1956; **32**(4994):669-73.
  23. Southgate BA. Studies in the epidemiology of East African leishmaniasis. 2. The human distribution and its determinants. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1964; **58**: 377-390.
  24. Kaddu JB. and Mutinga MJ. *Leishmania* in Kenyan Phlebotomine sand flies. II. Natural infection in the malphigian tubules of *Sergentomyia garnhami* and *Sergentomyia antennatus*. *Insect Science and Applications* 1984; **5**: 239-243.
  25. Schaefer KU; Kurtzhals JA; Sherwood JA; Githure JI; Kager PA. and Muller AS. Epidemiology and clinical manifestations of visceral and cutaneous leishmaniasis in Baringo District, Rift Valley, Kenya. A literature review. *Tropical Geographical Medicine* 1994; **46**(3):129-33.
  26. Jahn A. and Diesfeld HJ. Evaluation of a visually read ELISA for serodiagnosis and sero-epidemiological studies of kala-azar in the Baringo District, Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1983; **77**(4):451-4.
  27. Jahn A; Lemmett JM. and Diesfeld HJ. Seroepidemiological study on kala-azar in Baringo District, Kenya. *American Journal of Tropical Medicine and Hygiene* 1986; **89**:91-104.
  28. Mutero CM; Mutinga MJ; Ngindu AM; Kenya PR. and Amimo FA. Visceral leishmaniasis and malaria prevalence in West Pokot District, Kenya. *East African Medical Journal* 1992; **69**: 3-8.
  29. Mbatia PA; Githure JI; Kagai JM; Kirigi G; Kibati F; Wasunna K. and Koech DK. Evaluation of a standardized direct agglutination test (DAT) for the diagnosis of visceral leishmaniasis in Kenya. *Annals Tropical Medicine and Parasitology* 1999; **93**(7):703-10.
  30. Johnson RN; Lawyer PG; Ngumbi PM; Mebrahtu YB; Mwanyumba JP; Mosonik NC; Makasa SJ; Githure JI. and Roberts CR. Phlebotomine sand fly (Diptera: Psychodidae) seasonal distribution and infection rates in a defined focus of *Leishmania tropica*. *American Journal of Tropical Medicine and Hygiene* 1999; **60**(5):854-8.
  31. Marlet MV; Sang DK; Ritmeijer K; Muga RO; Onsongo J. and Davidson RN. Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, north-eastern Kenya, and south-eastern Ethiopia in 2000-01. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 2003; **97**(5): 515-8.
  32. Kungu A; Mutinga MJ. and Ngoka JM. Cutaneous leishmaniasis in Kenya. *East African Medical Journal* 1972; **48**: 458-465.
  33. Mutinga MJ. The animal reservoir of cutaneous leishmaniasis on Mt. Elgon, Kenya. *East African Medical Journal* 1975; **52**: 142-151.
  34. Sang DK; and Chance ML. Cutaneous leishmaniasis due to *Leishmania aethiops*, on Mount Elgon, Kenya. *Annals of Tropical Medicine and Parasitology* 1993; **87**(4): 349-357.
  35. Mutinga MJ; Massamba NN; Basimike M; Kamau CC; Amimo FA; Onyido AE; Omogo DM; Kyai FM. and Wachira DW. Cutaneous leishmaniasis in Kenya: *Sergentomyia garnhami* (Diptera Psychodidae), a possible vector of *Leishmania major* in Kitui District: a new focus of the disease. *East African Medical Journal* 1994; **71**(7): 424-428.
  36. Bin hazim AA; Githure JI; Muchemi GK. and Reid GD. Isolation of *Leishmania major* from a naturally infected vervet monkey (*Cercopithecus aethiops*) caught in Kiambu District, Kenya. *Journal of Parasitology* 1987; **73**(6):1278-9.

## PERSPECTIVE

---

37. Mebrahtu Y; Oster CN; Shatry AM; Hendricks LD; Githure JI; Rees PH; Perkins P. and Leeuwenburg J. Cutaneous leishmaniasis caused by *Leishmania tropica* in Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1987; **81**: 923-924.
38. Mebrahtu Y; Lawyer P; Githure JI; Kagar P; Leeuwenburg J; Perkins P; Oster C. and Hendricks LD. Indigenous human cutaneous leishmaniasis caused by *Leishmania tropica* in Kenya. *American Journal for Tropical Medicine and Hygiene* 1988; **39**:267-73.
39. Mebrahtu YB; Lawyer PG; Pamba H; Koech D; Perkins PV; Roberts CR; Were JB. and Hendricks LD. Biochemical characterization and zymodeme classification of *Leishmania* isolates from patients, vectors, and reservoir hosts in Kenya. *American Journal of Tropical Medicine and Hygiene* 1992; **47**(6):852-92.
40. Lawyer PG; Mebrahtu YB; Ngumbi PM; Mwanyumba P; Mbugua J; Kiilu G; Kipkoech D; Nzovu J. and Anjili CO. *Phlebotomus guggisbergi* (Diptera: Psychodidae), a vector of *Leishmania tropica* in Kenya. *American Journal for Tropical Medicine and Hygiene* 1991; **44**(3): 290-298.
41. Handman E. Leishmaniasis. Current status of vaccine development. *Clinical Microbiology and Reviews* 2001; **14**(2): 229-243.
42. World Health Organization, Geneva (WHO) .Control of leishmaniasis. Report of a WHO Expert Committee. Technical Report Series 1990; 793.
43. Lewin S; Schonian G; El Tai N; Oskam L; Bastien P. and Presber W. Strain typing in *Leishmania donovani* by using sequence-confirmed amplified region analysis. *International Journal of Parasitology* 2002; **32**(10):1267-76.
44. Makau JK; Anjili CO; Dunton RF; Lugalia RM. and Ngeiywa MM. Cutaneous leishmaniasis in BALB/c mice caused by a *Sauvoleishmania* species isolated from a plated lizard, *Gerrhosaurus major* (*Squamata cordylidae*). *East African Medical Journal* 1999; **76**(9):501
45. Mutinga MJ; Renapurkar DM; Wachira DW; Basimike M. and Mutero CM. A bioassay to evaluate the efficacy of permethrin-impregnated screens used against phlebotomine sand flies (Diptera: Psychodidae) in Baringo District of Kenya. *East African Medical Journal* 1993; **70**(3):168-70.
46. Lawyer PG; Githure JI; Anjili CO; Olobo JO; Koech DK. and Reid GD. Experimental transmission of *Leishmania major* to vervet monkeys (*Cercopithecus aethiops*) by bites of *Phlebotomus duboscqi* (Diptera: Psychodidae). *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1990;**84**(2):229-32.
47. Killick-Kendrick R. The life-cycle of *Leishmania* in the sand fly with special reference to the form infective to the vertebrate host. *Annales de parasitologie Humaine ET compare* 1990; **65**(1): 37-42.
48. Molina R; Lohse JM; Pulido F; Laguna F; Lopez-Velez R. and Alvar J. Infection of sand flies by humans coinfecting with *Leishmania infantum* and human immunodeficiency virus. *American Journal of Tropical Medicine and Hygiene* 1999; **60**(1):51-3.
49. Mutinga MJ. Phlebotomine sand flies (Diptera: Psychodidae): their importance and some aspects of control. *East African Medical Journal* 1996; **73**(1):48-9.
50. Balkew M; Gebre-Michael T; Berhe N; Ali A. and Hailu A. Leishmaniasis in the middle course of the Ethiopian Rift Valley: II. Entomological observations. *Ethiopian Medical Journal* 2002; **40**(3):271-82.
51. Mutinga MJ; Basimike M; Kamau CC. and Mutero CM. Epidemiology of leishmaniasis in Kenya. Natural host preference of wild caught phlebotomine sand flies in Baringo District, Kenya. *East African Medical Journal* 1990; **67**(5):319-27.
52. Ngumbi PM; Irungu LW; Robert LL; Gordon DM. and Githure JI. Abundances and nocturnal activities of phlebotomine sand flies (Diptera: Psychodidae) in termite hills and animal burrows in Baringo District, Kenya. *African Journal Of Health Sciences*, 1998; **5**(1): 28-34.

## PERSPECTIVE

---

53. Dedet JP; Derouin F; Hubert B; Shnur LF. and Chance ML. Isolation of *L. major* from *Mastomys erythroleucus* and *Tatera gambiana* in Senegal (West Africa). *Annals of Tropical Medicine and Parasitology* 1979; **73**: 433-437.
54. Beach R; Kiilu G; Hendricks LD; Oster C. and Leeuwenburg, J. (Cutaneous leishmaniasis in Kenya: transmission of *Leishmania major* to man by the bite of naturally infected *Phlebotomus duboscqi*. *Transactions of the Royal Society for Tropical Medicine and Hygiene*, 1984; **78**: 747-751.
55. Sang DK. and Sionkok TK. Cutaneous leishmaniasis and *Phlebotomus longipes* on Mount Elgon. *East African Medical Journal* 1983; **60**: 826.
56. Mutinga MJ. and Odhiambo TR. Cutaneous leishmaniasis in Kenya. III. The breeding and resting site of *Phlebotomus Pedifer* (Diptera; Phlebotomine) in Mount Elgon focus, Kenya. *Insect Science and Application* 1986; **7**: 175- 180.
57. Mutinga MJ; Ngoka JM; Schnur LF. and Chance ML. The isolation and identification of leishmanial parasites from domestic dogs in the Machakos District of Kenya, and the possible role of dogs as reservoirs of kala-azar in East Africa. *Annals of Tropical Medicine and Parasitology* 1980; **74**(2):139-44.
58. Mutinga MJ; Kihara SM; Lohding A; Muteru CM; Ngatia TA. Karanu F. Leishmaniasis in Kenya: description of leishmaniasis of a domestic goat from Transmara, Narok District, Kenya. *Tropical Medicine and Parasitology* 1989; **40**(2):91-6.
59. Williams AO; Mutinga J. and Rodgers M. Leishmaniasis in a domestic goat in Kenya. *Molecular Cell Probes* 1991; **5**(5):319-25.
60. Anjili CO; Ngichabe CK; Mbatia PA; Lugalia RM; Wamwayi HM. and Githure JI. Experimental infection of domestic sheep with culture-derived *Leishmania donovani* promastigotes. *Veterinary Parasitology* 1998; **31**; 74(2-4):315-8.
61. Anjili CO; Olobo JO; Mbatia PA; Robert L. and Githure JI. Experimental infection of domestic goats with *Leishmania major* through bites of infected *Phlebotomus duboscqi* and needle inoculation of culture-derived promastigotes. *Veterinary Research Communication* 1994; **18**(4):301-5.
62. Schaefer KU; Kurtzhals JA; Gachihi GS; Muller AS. and Kager PA. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1995; **89**(5):471-5.
63. De Raadt P. Leishmaniasis and world health. In ecologie des Leishmanioses, Colloques Internationaux du NC.N.R.S. (Editors). Paris: Editions du C.N.R.S. 1977;. 239: 313-315.
64. Brycesson A. Leishmaniasis. In: *Manson's Tropical Diseases, 20<sup>th</sup> Edition*, Cook, G. C. (Editor). London: W.B. Saunders, 1996; 1213-1243.
65. Boelaert M; Criel B; Leeuwenburg J; Van Damme W; Le Ray D. and Van der Stuyft P. Visceral leishmaniasis control: a public health perspective. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 2000; **94**(5):465-71.
66. Kager PA; Rees PH; Manguyu FM; Bhatt KM. and Bhatt SM. Splenic aspiration: experience in Kenya. *Tropical and Geographical Medicine* 1983; **35**: 125-131.
67. Chulay JD. and Brycesson AD. Quantitation of amastigotes of *Leishmania donovani* in smears of splenic aspirates from patients with visceral leishmaniasis. *American Journal Tropical Medicine and Hygiene* 1983. **32**(3): 475-479.
68. Kar K. Serodiagnosis of leishmaniasis. *Critical Review in Microbiology* 1995; **21**: 123-152.
69. Okong'o-Odera EA; Kurtzhals JA; Hey AS. and Kharazmi A. Measurement of serum antibodies against native *Leishmania* gp63 distinguish between ongoing and previous *L. donovani* infection. *APMIS* 1993; **101**(8):642-6.
70. Harith AE; Kolk AH; Kager PA; Leeuwenburg J; Faber FJ; Muigai R; Kiugu S. and Laarman JJ. Evaluation of a newly developed direct agglutination test

## PERSPECTIVE

---

- (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1987; **81**(4):603-6.
71. Boelaert M; El Safi S; Mousa H; Githure J; Mbatia P; Gurubacharya V; Shrestha J; Jacquet D; De Muynck A; Le Ray D. and Van der Stuyft P. Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis. *Tropical Medicine and International Health* 1999; **4**(1):31-7.
72. Mebrahtu Y; Lawyer P; Githure J; Were JB; Muigai R; Hendricks L; Leeuwenburg J; Koech D. and Roberts C. Visceral leishmaniasis unresponsive to pentostam caused by *Leishmania tropica* in Kenya. *American Journal of Tropical Medicine and Hygiene* 1989; **41**(3):289-94.
73. Mebrahtu Y; Lawyer P; Githure J; Kager P; Leeuwenburg J; Perkins P; Oster C. and Hendricks LD. Indigenous human cutaneous leishmaniasis caused by *Leishmania tropica* in Kenya. *American Journal of Tropical Medicine and Hygiene* 1988; **39**(3): 267-73.
74. van Eys GJ; Schoone GJ; Ligthart GS; Laarman JJ. and Terpstra WJ. Detection of *Leishmania* parasites by DNA *in situ* hybridization with non-radioactive probes. *Parasitology Research* 1987; **73**(3):199-202.
75. Massamba NN. Mutinga MJ. Recombinant kinetoplast DNA (kDNA) probe for identifying *Leishmania tropica*. *Acta Tropica* 1992; **52**(1):1-15.
76. Nuzum E; White F 3rd; Thakur C; Dietze R; Wages J; Grogl M. and Berman J. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. *Journal of Infectious Diseases* 1995; **171**(3):751-4.
77. Boelaert M and Dujardin JC. Diagnostic PCR with *Leishmania donovani* specificity. *Tropical Medicine and International Health*, 1999; **4**: 789.
78. Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G. and Mbugua J. Problems in the treatment of kala-azar: case report. *East African Medical Journal* 1995; **72**(6):406-8.
79. Chungu CN; Owate J; Pamba HO. and Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 1990; **84**(2):221-5.
80. Grogl M; Odula AMJ; Cordero LDC. and Kyle DE. *Leishmania* spp: development of pentostam-resistant clones *in vitro* by discontinuous drug exposure. *Experimental Parasitology* 1989; **69**:78-90.
81. United Nations Development Program/World Bank/World Health Organization. 1995. Tropical disease research. Progress 1975-94. Highlights 1993-94, p. 137. United Nations Development Program/World Bank/World Health Organization, Geneva.
82. Alexander JA; Stoskar R. and Russel DG. *Leishmania* species: models of intracellular parasitism. *Journal of Cell Science* 1999; **112**: 2993-3002.
83. Bighetti E; Hiruma-Lima JS; Gracioso C A. and Brito AR. Anti-inflammatory and antinociceptive effects in rodents of the essential oil of *Croton cajucara* Benth. *Journal of Pharmacy and Pharmacology* 1999; **51**:1447-1453.
84. Grogl M; Thomson TN. and Franke ED. Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous diseases. *American Journal for Tropical Medicine and Hygiene* 1992; **47**(1): 117-126.
85. Berenguer J; Moreno S; Cercenado E; Bernaldo de Quiros JC; Garcia de la Fuente A. and Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). *Annals of International Medicine* 1989; **111**: 129-132.
86. Altes J; Salas A; Riera M; Udina M; Galmes A; Balanzat J; Ballesteros A; Buades J; Salva F. and Villalonga C. Visceral leishmaniasis: another HIV-associated opportunistic infections? Report of eight cases and review of the literature. *AIDS* 1991; **5**:201-207.
87. Albrecht H; Stellbrink HJ; Gross G Berg G; Helmchen U. and Mensing H. Treatment of atypical leishmaniasis with

## PERSPECTIVE

---

- interferon g resulting in progression of Kaposi's sarcoma in an AIDS patient. *Clinical Investigations* 1994. **72**:1041–1047.
88. Torre-Cisneros J. and Villanueva JL. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfecting with the human immunodeficiency virus. *Clinical Infectious Diseases* 1995; **20**: 191 (Letter.)
89. Alvar J; Cañavate C; Gutiérrez-Solar B; Jiménez M; Laguna F; López-Vélez, R; Molina R. and Moreno J. *Leishmania* and human immunodeficiency virus co-infection: the first 10 years. *Clinical Microbiology and Reviews* 1997; **10**:298-319.
90. Croft SL. and Yardley V. Chemotherapy of leishmaniasis. *Current Pharmaceutical Descriptions* 2002; **8**:319-342.
91. Rates SM. Plants as source of drugs. *Toxicon* 2001; **39**:603-613.
92. Rono MK; Rukungu G; Ndiege I; Musau R; Were CL; Muthaura C; Ngumbi P. and Tonui WK. Bio-prospecting for anti-leishmanials from plants used for Kala-azar therapy by traditional healers in Baringo District of Kenya (Manuscript in preparation).
93. Mbatia PA; Abok K; Orago AS; Anjili CO; Kagai JM; Githure JI. and Koech DK. Pristane (2,6,10,14-Tetramethylpentadecane) inhibits disease progression in *Leishmania*-infected Balb/c mice. *African Journal of Health Sciences* 1994; **1**(4):157-159.
94. Mbatia PA; Abok K; Anjili CO; Orago AS; Kagai JM; Githure JI. and Koech DK. Screening of metal ion chelators against *Leishmania donovani*-infected Syrian hamsters. *African Journal of Health Sciences* 1995; **2**(1):223-227.
95. Armijos RX; Weigel MM; Aviles H; Maldonado R. and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up. *Journal of Infectious Diseases* 1998; **177**: 1352-1357.
96. Momeni AZ; Jalayer T; Emamjomeh M; Khamesipour A; Zicker F; Ghassemi RL; Dowlati Y; Sharifi I; Aminjavaheri M; Shafiel A; Alimohammadian MH; Hashemi-Fasharki R; Nasser K; Godal T; Smith PG. and Modabber F. A randomized, double blind, controlled trial of a killed *L. major* vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. *Vaccine* 1999; **17**: 466-472.
97. Khalil EA; ELHassan AM; Zijlstra EE; Mukhtar MM; Ghalib HW; Musa B; Ibrahim ME; Kamil AA; Elsheikh M; Babiker A. and Modabber F. Autoclaved *Leishmania major* vaccine for prevention of visceral leishmaniasis: a randomized, double blind, BCG-controlled trial in Sudan. *Lancet* 2000; **356**: 1565-1569.
98. Titus R; Gueiros-Filho F; de Freitas LA. and Beverley SM. Development of a safe live *Leishmania* vaccine line by gene replacement. *Proceedings of the National Academy of Sciences USA* 1995; **92**: 10267-10271.
99. Connell ND; Medina-Acosta E; McMaster WR; Bloom BR. and Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant Baccille Calmette-Guerin expressing the *Leishmania* surface protease gp63. *Proceedings of the National Academy of Sciences USA* 1993; **90**: 11473-11477.
100. McMahan-Pratt D., Rodriguez D; Rodriguez JR; Zhang Y; Manson K; Bergman C; Rivas L; Rodriguez JF; Lohman KL. and Ruddle NH. Recombinant vaccinia vaccine viruses expressing GP46/M-2 protects against *Leishmania* infection. *Infection and Immunity* 1993; **61**: 3351-3359.
101. Xu D., McSolely SJ; Chatfield SN; Dougan G. and Liew FY. Protection against *Leishmania major* infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated *Salmonella typhimurium* (AroA<sup>-</sup>AroD<sup>-</sup>). *Immunology* 1995; **85**: 1-7.
102. Mougneau E; Altare F; Wakil AE; Zheng S; Coppola T; Wang ZE; Waldmann R; Locksley RM. and Glaichenhaus N. Expression cloning of a protective *Leishmania* antigen. *Science* 1995; **268**: 563-566.

## PERSPECTIVE

---

103. Rachamin N. and Jaffe CL. Pure protein from *Leishmania donovani* protects mice against both cutaneous and visceral leishmaniasis. *Journal of Immunology* 1993; **150**: 2322-2331.
104. Spitzer N; Jardim A; Lippert D. and Olafson R. Long-term protection of mice against *Leishmania major* with a synthetic peptide vaccine. *Vaccine* 1999; **17**: 1298-1300.
105. Xu D. and Liew FY. Genetic vaccination against leishmaniasis. *Vaccine* 1994; **12**: 1534-1536.
106. Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N. and Seder RA. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with *Leishmania major*. *Journal of Experimental Medicine* 1997; **186**: 1137-1147.
107. Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL. and Handman E. Vaccination with recombinant parasite surface antigen 2 from *Leishmania major* induces a Th1 type of immune response but does not protect against infection. *Vaccine* 1998; **16**: 2077-2084.
108. Onyalo JA; Mwala DM; Anjili CO; Orago AS. and Tonui WK. Vaccinations with live-attenuated *Leishmania major* promastigotes and challenge infection with *L. major* in BALB/c mice. *East African Medical Journal* 2005; **82**(4):193-7.
109. Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK and Titus RG. Immunization with *Leishmania major* exogenous antigens protects susceptible BALB/c mice against challenge infection with *L. major*. *Infection and Immunity* 2004; **72**(10):5654-61.
110. Tonui WK; Mpoke SS; Orago AS; Turco SJ; Mbatia PA. and Mkoji GM. *Leishmania donovani*-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (*Mesocricetus auratus*) and BALB/c mice against *Leishmania donovani*. *Onderstepoort Journal of Veterinary Research* 2003; **70**(4):255-63.
111. Karanja R; Ingonga J; Mwangi M; Mwala D; Magambo J. and Tonui W. Immunization with a combination of *Leishmania major* Lipophosphoglycan (LPG) and *Phlebotomus duboscqi* salivary gland lysates (SGLs) abrogates protective effect of LPG against *L. major* in Balb/c mice. *East African Medical Journal* 2005; In Press
112. Tonui WK. *Leishmania* transmission-blocking vaccines: a review. *East African Medical Journal* 1999; **76**(2):93-96.
113. Tonui WK; Mbatia PA; Anjili CO; Orago AS; Turco SJ; Githure JI. and Koech DK. Transmission blocking vaccine studies in leishmaniasis. I: Lipophosphoglycan (LPG) is a promising transmission blocking vaccine candidate against cutaneous leishmaniasis *East African Medical Journal* 2001; **78**(2):84-89.
114. Tonui WK; Mbatia PA; Anjili CO; Orago AS; Turco SJ; Githure JI. and Koech DK. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using *Leishmania major* derived 63 kilodalton glycoprotein, lipophosphoglycan, and whole parasite antigens on the course of *L. major* infection in BALB/c mice. *East African Medical Journal* 2001; **78**(2):90-2.
115. Tonui WK; Ngumbi PM; Mpoke SS; Orago AS; Mbatia PA; Turco SJ. and Mkoji GM. *Leishmania major-Phlebotomus duboscqi* interactions: inhibition of anti-LPG antibodies and characterisation of two proteins with shared epitopes. *East African Medical Journal* 2004; **81**(2):97-103.
116. Mbatia PA; Abok K; Orago AS; Anjili CO; Githure JI; Kagai JM. and Koech DK. Establishment of an appropriate inoculum dose of *Leishmania donovani* promastigotes required to establish a visceral infection in laboratory animal rodent models. *African Journal for Health Sciences* 1994; **1**(4):165-168.
117. Githure JI; Reid GD; Binhazim AA; Anjili CO; Shatry AM. and Hendricks LD. *Leishmania major*: the suitability of East African nonhuman primates as animal models for cutaneous leishmaniasis. *Experimental Parasitology* 1987; **64**(3):438-47.

## PERSPECTIVE

---

118. Olobo JO; Gicheru MM. and Anjili CO. The African Green Monkey model for cutaneous and visceral leishmaniasis. *Trends in Parasitology* 2001; **17**(12):588-92.
119. Olobo JO; Anjili CO; Gicheru MM; Mbatia PA; Kariuki TM, Githure JJ; Koech DK. and McMaster WR. Vaccination of vervet monkeys against cutaneous leishmaniasis using recombinant *Leishmania major* surface glycoprotein' (gp63). *Veterinary Parasitology* 1995; **60**(3-4):199-212.
120. Gicheru MM; Olobo JO; Anjili CO; Orago AS; Modabber F. and Scott P. Vervet monkeys vaccinated with killed *Leishmania major* parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. *Infection and Immunity* 2001; **69**(1):245-51.
121. Gicheru MM; Olobo JO. and Anjili CO. Heterologous protection by *Leishmania donovani* for *Leishmania major* infections in the vervet monkey model of the disease. *Experimental Parasitology* 1997; **85**(2):109-16.